Docetaxel/5'DFUR or Docetaxel for advanced or recurrent gastric cancer as 2nd line chemotherapy

INTERVENTION: Docetaxel 60 mg/m2 iv (tri‐weekly) and 5'DFUR 600 mg/body orally (daily), as one course. This is continued until PD or unacceptable toxicity occurs or patients choose to discontinue the treatment. Docetaxel 60 mg/m2 iv (tri‐weekly), as one course. This is continued until PD or unacceptable toxicity occurs or patients choose to discontinue the treatment. CONDITION: gastric cancer PRIMARY OUTCOME: response rate, survival, toxicity INCLUSION CRITERIA: 1. histologically proven gastric cancer 2. measurable or evaluable leisions 3. second line chemotherapy 4. adequate interval after first line chemotherapy 5. performance status 0‐2 6. adequate organ function 7. estimated survival period: more than 3 months 8. written informed consent